Irritable Bowel Syndrome Ibs clinical trials

Explore recruiting irritable bowel syndrome ibs clinical trials.

Recruiting irritable bowel syndrome ibs studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Irritable Bowel Syndrome Ibs trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irritable bowel syndrome (IBS-M)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irritable bowel syndrome (IBS-D)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

ICEBOAT. A prospective, multi-center, double blind randomized trial of fecal microbiota transplantation (FMT) delivered by capsule versus placebo in severe irritable bowel syndrome (IBS)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting with Symptoms Associated with Irritable Bowel Syndrome with code GSL-01-001

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A double-blind, randomized, placebo-controlled, multicenter trial evaluating the efficacy and safety of Saccharomyces boulardii CNCM I-745 in adult patients with non-constipated Irritable Bowel Syndrome.

Portugal, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Irritable Bowel Syndrome Ibs trials by city

Irritable Bowel Syndrome Ibs in Toronto Irritable Bowel Syndrome Ibs in Vancouver Irritable Bowel Syndrome Ibs in Montreal Irritable Bowel Syndrome Ibs in Calgary Irritable Bowel Syndrome Ibs in Edmonton Irritable Bowel Syndrome Ibs in Ottawa Irritable Bowel Syndrome Ibs in Winnipeg Irritable Bowel Syndrome Ibs in Quebec City Irritable Bowel Syndrome Ibs in Hamilton Irritable Bowel Syndrome Ibs in Kitchener Irritable Bowel Syndrome Ibs in London Irritable Bowel Syndrome Ibs in Halifax Irritable Bowel Syndrome Ibs in New York Irritable Bowel Syndrome Ibs in Los Angeles Irritable Bowel Syndrome Ibs in Chicago Irritable Bowel Syndrome Ibs in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease